10 Best Upside Stocks to Buy According to Hedge Funds
On June 22, Stephen Parker, JPMorgan Private Bank Co-Head of Global Investment Strategy, joined CNBC's 'Squawk Box' to share his outlook on the current state of the market, which...
Posts Tagged ‘BridgeBio Pharma Inc. (NASDAQ:BBIO)’
8 Most Promising Biotech Stocks to Buy Now
On January 14, Reuters reported that investors foresee a comeback in the US biotech sector in 2026, with more IPO activity and stronger deal-making as legislative risks ease.
Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential
Tom Steyer, the billionaire investor and founder of Farallon Capital, has undergone a profound evolution from a pioneer of absolute-return hedge fund strategies to a leading architect...
Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here’s Why
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best high growth healthcare stocks to buy now. Mizuho lifted the price target on BridgeBio Pharma, Inc.
11 High Growth Healthcare Stocks to Buy Now
On March 26, Stephanie Link, Hightower chief investment strategist, appeared on CNBC's ‘Squawk Box’ to talk about the latest market trends, where investors can find opportunities...
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade
BridgeBio saw its share prices jump by 13.22 percent on Tuesday to close at $74.32 apiece, as investors took path from an investment firm’s double-digit price target upgrade...
10 Stocks Investors Are Watching: WiPro, USAR, NIO, and More
Ten stocks soared higher on Tuesday, bucking a lackluster performance in the broader market, as investors took path from a flurry of positive developments including analyst ratings...
Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating
On February 25, 2026, Truist analyst Danielle Brill raised the firm’s price target on BridgeBio Pharma, Inc.
10 Fastest Growing NASDAQ Stocks to Buy
High growth stocks have once again taken center stage, and major asset managers argue that earnings momentum remains the decisive factor.
BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential.
10 Stocks With Explosive Growth Potential
On February 26, Darren Sissons, partner and portfolio manager at Campbell, Lee & Ross Investment Management, appeared on BNN Bloomberg to share his outlook on Global and Technology...
BoFA Notes BridgeBio Pharma, Inc. (BBIO)’s Upcoming Q4 Earnings May Have Limited Market Impact
TheFly reported on February 3 that Bank of America analyst Jason Zemansky raised its price target on BBIO to $88 from $85 and maintained a Buy rating on the shares.
BridgeBio (BBIO) Tumbles 15%, Mirrors Marked Bleed
BridgeBio fell by 15.24 percent on Thursday to close at $63.73 apiece, mirroring the broader market decline amid a highly pessimistic environment, while repositioning portfolios...
13 Best Russell 2000 Stocks to Buy Right Now
On January 6, Royce Investment Partners released their outlook for the small-cap stocks in 2026.
Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results
TheFly reported on January 8 that Truist raised its price target on BBIO to $86 from $80 while maintaining a Buy rating.
Top 10 Oncology Stocks to Buy Now
The oncology market in the United States was estimated at $81.34 billion in 2025 and is expected to reach $211.78 billion by 2034 with a compound annual growth rate of 11.75...
BridgeBio Pharma (BBIO) Soars to All-Time High on Stellar Drug Trial Result
BridgeBio rallied for a third straight day on Monday to hit a new all-time high as investors snapped up shares following the stellar results of its final clinical trial for the...
UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) Retains $68 Target on Strong Launch Dynamics
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is among the most promising biotech stocks to buy according to hedge funds.
7 Most Promising Biotech Stocks to Buy According to Hedge Funds
If there’s one sector that is gaining popularity each day, it’s definitely the biotechnology market.
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
BridgeBio Pharma’s Encaleret Shows Positive Phase 2 Results, Normalizes Calcium in Post-Surgical Hypoparathyroidism
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the most promising long-term stocks to buy.
11 Best Performing Long Term Stocks According to Analysts
On September 19, Alli McCartney, Managing Director at UBS Private Wealth Management, and Philip Straehl, CIO Americas at Morningstar Wealth, joined CNBC to the rate cuts, market...
12 Most Promising Long-Term Stocks to Buy
On September 12, Abby Joseph Cohen, Columbia Business School professor and former Goldman Sachs partner & chief US strategist, joined 'Squawk Box' on CNBC to discuss the latest...
13 Best Mid Cap Growth Stocks to Buy According to Hedge Funds
On August 26, Courtney Garcia, Payne Capital Management senior wealth advisor, joined CNBC television for an interview to discuss whether investors should continue buying in the...
TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO) on Strong Attruby Sales
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best Russell 2000 stocks to buy now.
12 Best Russell 2000 Stocks to Buy Now
In its Weekly Market Monitor report for the week ending August 8, 2025, Goldman Sachs noted that U.S. equities had firmly recovered from their April lows.
Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best strong buy healthcare stocks to buy now.
10 Best Strong Buy Healthcare Stocks to Buy Now
On July 21, Jared Holz, Mizuho health care sector strategist, appeared on CNBC's 'The Exchange' to talk about whether any opportunity plays exist within the healthcare sector, ...
Truist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the best biotech stocks to buy according to billionaire Steve Cohen.
10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen
Steve Cohen, whose success at SAC Capital made him one of the most successful hedge fund managers on Wall Street, is a worried man.
BridgeBio Pharma Raises $300M Through Partial European Royalty Monetization for BEYONTTRA
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the best high short interest stocks with huge upside potential.
10 Best High Short Interest Stocks With Huge Upside Potential
Abby Yoder, JPMorgan Private Bank's chief equity strategist, joined CNBC's 'Closing Bell' on July 2 to discuss the market's momentum as stocks began the second half of the year...
BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights
BridgeBio Pharma dropped for a second day on Monday, shedding 3.74 percent to finish at $43.18 apiece as investors digested the sale of royalty rights from its heart drug Beyonttra...
Piper Sandler Reaffirms Overweight Rating on BridgeBio Ahead of Phase 3 CALIBRATE Results
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential.
Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform’ Rating
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 10 biotech stocks screaming a buy.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market.
Billionaire Stan Druckenmiller’s 10 Stock Picks with Huge Upside Potential
Stanley Druckenmiller, an American billionaire investor, is the founder of Duquesne Capital.
BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 13 Biotech Stocks with Huge Upside Potential. In a recent report, Raghuram Selvaraju, an expert at H.C.
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
BMO Maintains Hold on BridgeBio (BBIO) Amid Intensifying Competition
On June 3, BMO Capital Markets analyst Kostas Biliouris reiterated a Hold rating on BridgeBio Pharma Inc. (NASDAQ:BBIO) with an unchanged price target of $37.
BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment
On May 19, BridgeBio Pharma, Inc.
Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential
Ole Andreas Halvorsen is one of the prominent names among former employees of Julian Robertson's Tiger Management.
10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
10 Best Performing Mid Cap Stocks to Buy According to Analysts
On February 7, Simeon Hyman, Global Investment Strategist at ProShares Advisors, appeared on CNBC to discuss the upcoming jobs report and its expected impact on the market.
10 Best Performing Pharma Stocks So Far in 2025
On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on 'Squawk Box' to discuss the potential challenges and opportunities the pharmaceutical industry may...
12 Best Healthcare Stocks to Buy According to Analysts
McKinsey reported that, since 2019, the US healthcare industry witnessed significant financial pressure.
10 Unstoppable Stocks to Buy in 2025
As per the recent earnings update by FactSet dated 24th January 2025, the Q4 2024 earnings season for the S&P 500 has seen a strong start.
Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks
Andreas Halvorsen is a prominent Norwegian hedge fund manager and the co-founder of Viking Global, one of the most successful equity-focused hedge funds in the world.
10 Worst Performing Biotech Stocks in 2024
Biotechnology stocks are among the most volatile in the market due to their high risk.
Hedge Fund Resource Center
